(Q44789615)

6 December 2017

title

Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers (English)

1 reference

6 December 2017

1 reference

Julia Kirchheiner

1

1 reference

6 December 2017

Ingolf Meineke

2

1 reference

6 December 2017

Göran Müller

3

1 reference

6 December 2017

Steffen Bauer

4

1 reference

6 December 2017

Wolfgang Rohde

5

1 reference

6 December 2017

Christian Meisel

6

1 reference

6 December 2017

Ivar Roots

7

1 reference

6 December 2017

Jürgen Brockmöller

8

1 reference

6 December 2017

publication date

1 January 2004

1 reference

Clinical Pharmacokinetics

6 December 2017

published in

1 reference

6 December 2017

volume

43

1 reference

6 December 2017

issue

4

1 reference

6 December 2017

page(s)

267-278

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200443040-00005

6 December 2017

exact match

0 references

cites work

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers

1 reference

12 December 2020

A novel D-phenylalanine-derivative hypoglycemic agent A-4166 increases cytosolic free Ca2+ in rat pancreatic beta-cells by stimulating Ca2+ influx

1 reference

12 December 2020

N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents

1 reference

12 December 2020

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

1 reference

12 December 2020

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

1 reference

12 December 2020

Fully automated nucleic acid extraction: MagNA Pure LC

1 reference

12 December 2020

Pharmacokinetics and metabolism of nateglinide in humans.

1 reference

12 December 2020

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

1 reference

12 December 2020

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism

1 reference

12 December 2020

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences

1 reference

12 December 2020

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

1 reference

12 December 2020

Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent

1 reference

12 December 2020

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

1 reference

12 December 2020

Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo

1 reference

12 December 2020

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1 reference

12 December 2020

Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.

1 reference

12 December 2020

Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

1 reference

12 December 2020

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

1 reference

12 December 2020

Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection

1 reference

12 December 2020

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

1 reference

12 December 2020

Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.

1 reference

12 December 2020

A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic beta-cells

1 reference

12 December 2020

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients

1 reference

12 December 2020

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

12 December 2020

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

1 reference

12 December 2020

Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis

1 reference

12 December 2020

Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease.

1 reference

12 December 2020

Genetic analysis of the human cytochrome P450 CYP2C9 locus

1 reference

12 December 2020

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans

1 reference

12 December 2020

10.2165/00003088-200443040-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

6 December 2017

1031696453

0 references

1 reference